Quetiapine Augmentation for Treatment-resistant PTSD

Phase 4 Completed 124 enrolled VA Office of Research and Development AstraZeneca · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the response of veterans with PTSD without an optimal response to paroxetine to quetiapine augmentation versus placebo.

Timeline

Start: 2006-01
Primary completion: 2008-12
Completion: 2009-05

Outcome

Met primary endpoint

registry analysis (unspecified test); Arm 2 OL Paroxetine + DB Placebo vs Arm 3: OL Paroxetine + DB Quetiapine; p <0.05; Mixed Models Analysis NCT00292370 ↗

Publications

Background Weathers FW, Keane TM, Davidson JR. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety. 2001;13(3):132-56. doi: 10.1002/da.1029.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Quetiapine	Small molecule	800 mg	—
Background	Paroxetine	Small molecule	60 mg	—